Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957453 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL1007447 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL25933046 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL600021 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| Hydrochloric Acid SCHEMBL11095114 | 0.96 | SLC7A5 (0.59) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL4632980 | 0.96 | SLC7A5 (0.59) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL4633860 | 0.96 | SLC7A5 (0.59) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL28153656 | 0.89 | SLC7A5 (0.53) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL3930054 | 0.86 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL5326967 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| CN-119912365-A | Taurine refining process and application thereof | 江阴华昌食品添加剂有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4426741-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | Hangzhou DAC Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2003047558-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE INHIBITORS | GENSET S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
| EP-1009770-A1 | PEPTIDES CONTAINING AN ARGININE MIMETIC FOR THE TREATMENT OF BONE METABOLIC DISORDERS, THEIR PRODUCTION, AND DRUGS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012970-A1 | PEPTIDES CONTAINING AN ARGININE MIMETIC FOR THE TREATMENT OF BONE METABOLIC DISORDERS, THEIR PRODUCTION, AND DRUGS CONTAINING THESE COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
| EP-0902036-A1 | Peptide containing an arginine mimetic for the treatment of osteoporosis, their production, and drugs containing these compounds | Roche Diagnostics GmbH (DE) | 1999-03-17 | — | — | EP | disclosed |
| US-5695737-A | CONTRAST MEDIA FOR NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5610141-A | CELL DIVISION STIMULANT | NYCOMED IMAGING AS (NO) | 1997-03-11 | — | — | US | disclosed |
| EP-0673388-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-09-27 | — | — | EP | disclosed |
| US-5362477-A | 19F magnetic resonance imaging agents which include a nitroxide moiety | MALLINCKRODT MEDICAL, INC. (US) | 1994-11-08 | — | — | US | disclosed |
| WO-1993024523-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | SLC7A5 210/4885SLC1A3 105/4885SLC1A2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.